Verastem Reports First Full Year Product Revenue, Advances KRAS G12D Inhibitor to Registration-Directed Trials

summarizeSummary

Verastem reported its first full year of product revenue totaling $30.9 million for AVMAPKI FAKZYNJA CO-PACK, alongside significant pipeline advancements for its KRAS G12D inhibitor VS-7375, including Fast Track Designation and plans for registration-directed trials. The company maintains a strong cash position with a runway into the first half of 2027, despite a substantial net loss.

check_boxKey Events

• First Full Year Product Revenue Reported

  Verastem recognized $30.9 million in net product revenue for the full year 2025 from AVMAPKI FAKZYNJA CO-PACK, following its accelerated FDA approval in May 2025 for KRAS-mutated recurrent LGSOC.

• Strong Cash Position and Runway

  The company ended 2025 with $205.0 million in cash, cash equivalents, and investments. Pro-forma cash, including $29.4 million from January 2026 warrant exercises, totals $234.4 million, providing a cash runway into the first half of 2027.

• KRAS G12D Inhibitor (VS-7375) Advances to Registration-Directed Trials

  VS-7375 received Fast Track Designation from the FDA for pancreatic ductal adenocarcinoma (PDAC) and the company plans to initiate disease-specific Phase 2 registration-directed trials for 2L PDAC, 2L/3L NSCLC, and 2L+ colorectal cancer (CRC).

• NCCN Guidelines Update for AVMAPKI FAKZYNJA CO-PACK

  The National Comprehensive Cancer Network (NCCN) retained its Category 2A recommendation for KRAS-mutated recurrent LGSOC but did not expand it to include KRAS wild-type patients, a setback for broader indication.

auto_awesomeAnalysis

Verastem's 10-K filing highlights a pivotal year with the first full year of product revenue from AVMAPKI FAKZYNJA CO-PACK, a significant milestone for a biopharmaceutical company. The company also demonstrated substantial progress in its pipeline, particularly with the KRAS G12D inhibitor VS-7375, which received Fast Track Designation and is moving towards registration-directed trials. While the company reported a considerable net loss, this is typical for a biotech in its commercialization and R&D phases. The strong cash position, bolstered by recent financing, provides a runway into the first half of 2027, offering financial stability for ongoing operations and clinical programs. The NCCN guideline update, while a setback for broader label expansion for AVMAPKI FAKZYNJA CO-PACK, does not negate the existing approval or the ongoing confirmatory trials. The amendment to the Note Purchase Agreement is a minor financing adjustment.